Johnson & Johnson (JNJ) is set to receive European Union approval for its $21.3 billion purchase of Swiss medical device company Synthes Inc. (SYST.VX) after making concessions related to dominance in the trauma products market, Reuters reported Thursday, citing a person familiar with the situation.

Approval could take place before an April 26 EU deadline, Reuters reported.

Full story at http://www.reuters.com/article/2012/03/15/jj-synthes-eu-idUSL5E8EF6LX20120315

-Dow Jones Newswires; 212-416-2900